DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Mespirenone
Mespirenone
Compositions Comprising Drospirenone Molecularly
Ovid MEDLINE(R)
Pharmaceutical Appendix to the Tariff Schedule 2
Nomenclature of Steroids
Marrakesh Agreement Establishing the World Trade Organization
Docking Molecular Analysis of Potential Aldosterone Antagonists
(12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
(12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
Stembook 2018.Pdf
Customs Tariff - Schedule
Customs Tariff - Schedule
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Customs Tariff - Schedule
A Computational Study of the Substrate Conversion and Selective Inhibition of Aldosterone Synthase
Pharmaabkommen A1 E
Tariffa Integrata Delle Comunità Europee (TARIC) Volume IV — Allegati (96/C 98 A/01 )
(12) Patent Application Publication (10) Pub. No.: US 2006/0018937 A1 Friedman Et Al
Top View
Customs Tariff - Schedule Xxi - 1
III IIII US005529992A United States Patent (19) 11 Patent Number: 5,529,992 Weber 45) Date of Patent: Jun
(12) United States Patent (10) Patent No.: US 8,715,735 B2 Funke Et Al
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Spironolactone - Wikipedia
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Mineralocorticoid Receptor Antagonists: Achieving Cardiovascular Benefit with Minimized Renal Side Effects? European Heart Journal 34 2426–2428
Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
Docking Molecular Analysis of Potential Aldosterone Antagonists
Handbook of Experimental Pharmacology Volume 117
Us 2008/0206161 A1 S. Valve
Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement
Pharmaceutical Appendix to the Tariff Schedule 2
Schedule Clxxiii - European Union
Mineralocorticoid Receptor Antagonists: Achieving Cardiovascular Benefit with Minimized Renal Side Effects? European Heart Journal 34 2426–2428
(12) Patent Application Publication (10) Pub. No.: US 2005/0207990 A1 Funke Et Al